Literature DB >> 30114486

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.

Catherine Le Berre1, Damien Loeuille2, Laurent Peyrin-Biroulet3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30114486     DOI： 10.1016/j.cgh.2018.08.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  7 in total

Review 1.  Is tofacitinib a game-changing drug for ulcerative colitis?

Authors:  Fernando Magro; Maria Manuela Estevinho
Journal:  United European Gastroenterol J       Date:  2020-06-18       Impact factor: 4.623

Review 2.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

3.  A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib.

Authors:  Pilar Taberner Bonastre; Gisela Torres Vicente; Manuel Cano-Marron; Eva Sese Abizanda; Tania Dalila Volta Pardo; Joan Antoni Schoenenberger-Arnaiz
Journal:  Eur J Hosp Pharm       Date:  2021-01-25

4.  Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.

Authors:  David T Rubin; Walter Reinisch; Thomas Greuter; Paulo G Kotze; Marcia Pinheiro; Rajiv Mundayat; Eric Maller; Marc Fellmann; Nervin Lawendy; Irene Modesto; Stephan R Vavricka; Gary R Lichtenstein
Journal:  Therap Adv Gastroenterol       Date:  2021-05-16       Impact factor: 4.409

5.  Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.

Authors:  Quazim A Alayo; Aava Khatiwada; Anish Patel; Maria Zulfiqar; Anas Gremida; Alexandra Gutierrez; Richard P Rood; Matthew A Ciorba; George Christophi; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 7.290

Review 6.  Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.

Authors:  Nikoleta Zioga; Dionysios Kogias; Vasiliki Lampropoulou; Nikolaos Kafalis; Charalampos Papagoras
Journal:  Mediterr J Rheumatol       Date:  2022-04-15

7.  Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Authors:  Laurent Goessens; Jean-Frédéric Colombel; An Outtier; Marc Ferrante; Joao Sabino; Ciaran Judge; Reza Saeidi; Louise Rabbitt; Alessandro Armuzzi; Eugeni Domenech; George Michalopoulos; Anneline Cremer; Francisco Javier García-Alonso; Tamas Molnar; Konstantinos Karmiris; Krisztina Gecse; Joep Van Oostrom; Mark Löwenberg; Klaudia Farkas; Raja Atreya; Davide Giuseppe Ribaldone; Christian Selinger; Frank Hoentjen; Benoit Bihin; Shaji Sebastian; Jean-François Rahier
Journal:  United European Gastroenterol J       Date:  2021-10-25       Impact factor: 4.623
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.